What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cardiology
- Surgery
His main research concerns Internal medicine, Cardiology, Atrial fibrillation, Stroke and Task force.
The concepts of his Internal medicine study are interwoven with issues in Anesthesia and Surgery.
His research on Cardiology frequently connects to adjacent areas such as Guideline.
His Guideline research includes elements of Platelet aggregation inhibitor, Disease, Alternative medicine and Percutaneous coronary intervention.
His Atrial fibrillation study combines topics in areas such as Thrombosis, ANTIARRHYTHMIA AGENTS and Heart Rhythm.
His Stroke study combines topics from a wide range of disciplines, such as Rivaroxaban, Framingham Risk Score, Antithrombotic, Vitamin K antagonist and Ximelagatran.
His most cited work include:
- ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) (7962 citations)
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (6202 citations)
- ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) (2927 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Cardiology, Atrial fibrillation, Stroke and Warfarin.
Internal medicine and Surgery are frequently intertwined in his study.
His research combines Guideline and Cardiology.
His Atrial fibrillation research incorporates themes from Anesthesia, Aspirin and Randomized controlled trial.
His study in Stroke is interdisciplinary in nature, drawing from both Clinical trial, Vitamin K antagonist, Intensive care medicine, Hazard ratio and Risk factor.
His studies in Warfarin integrate themes in fields like Anticoagulant and Confidence interval.
He most often published in these fields:
- Internal medicine (74.04%)
- Cardiology (60.88%)
- Atrial fibrillation (52.10%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (74.04%)
- Atrial fibrillation (52.10%)
- Cardiology (60.88%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Atrial fibrillation, Cardiology, Stroke and In patient.
His work on Internal medicine deals in particular with Warfarin, Rivaroxaban, Myocardial infarction, Incidence and Confidence interval.
His Warfarin research integrates issues from Thrombolysis and Lower risk.
Jonathan L. Halperin has included themes like Antithrombotic and Percutaneous coronary intervention in his Atrial fibrillation study.
His Cardiology research incorporates elements of Aspirin and Randomized controlled trial.
His Stroke study incorporates themes from Prospective cohort study, Clinical trial, Risk factor and Hazard ratio.
Between 2016 and 2021, his most popular works were:
- The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2 (170 citations)
- Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. (116 citations)
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (114 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Stroke
Jonathan L. Halperin mainly investigates Atrial fibrillation, Internal medicine, Stroke, Cardiology and Rivaroxaban.
His Atrial fibrillation research includes themes of Anesthesia, Prospective cohort study and Antithrombotic.
Jonathan L. Halperin combines subjects such as Lower risk, Clinical trial, Intensive care medicine and Hazard ratio with his study of Stroke.
Many of his research projects under Cardiology are closely connected to Task force with Task force, tying the diverse disciplines of science together.
His Rivaroxaban research is multidisciplinary, relying on both Placebo, Randomized controlled trial and Percutaneous coronary intervention.
His research in Warfarin intersects with topics in Embolism, Vascular closure device, Thrombolysis, Stent and Anticoagulant.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
